qQ-lab Daily-IBS for Irritable Bowel Syndrome

NCT03964103 | Completed

• 1 other identifier: qQ-lab daily-IBS
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

• Primary purpose: To assess satisfaction with overall improvement in symptoms, including individual bowel symptoms, after 4 weeks of administration of gQ-lab to patients with irritable bowel syndrome (IBS).
• Secondary purposes: To assess the correlation between intestinal attachment and therapeutic effects of gQ-lab through the visual analog scale (VAS) assessment of each IBS-related symptom and measurement of changes in quality of life and fecal flora in the placebo group and gQ-lab group after 4 weeks of gQ-lab administration. To assess safety, including adverse reactions, vital signs (including weight), physical examination, and changes in blood test results. To examine the rate of positive gut quotient (gQ) values in patients diagnosed with IBS as per the ROME III criteria. Further, to examine how the ROME III-based symptom scale score compared with that of the quality of life scale in the gQ questionnaire.

Conditions

Irritable Bowel Syndrome (IBS)

Outcome Measures

Primary Outcomes (1)

• Symptom questionnaire survey (VAS score)

  To assess satisfaction with overall improvement in bowel symptoms, after 4 weeks of administration of GQ lab to patients with irritable bowel syndrome (IBS). The range of the VAS score is 1 to 10. The lower the value of the VAS score, the better. The value of the endpoint (4 weeks) is compared in the placebo group versus the treatment group.

  4 weeks

Study Arms (2)

gQ-lab daily

EXPERIMENTAL

Dietary Supplement: gQ-lab daily

Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

gQ-lab daily DIETARY_SUPPLEMENT

probiotics

gQ-lab daily

Placebo DIETARY_SUPPLEMENT

powdered skim milk, lactose

Placebo

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Korean men and women aged over 19 and 80
• Patients with IBS meeting the ROME III criteria (Diagnosed with IBS with abdominal discomfort or abdominal pain in the past 3 months and meeting at least two of the following conditions: (1) improvement in defecation; (2) onset of symptoms associated with changes in stool frequency; (3) association with changes in stool form)
• Patients who underwent colonoscopy in the past 5 years and have been confirmed to have no organ abnormalities
• Women who are surgically infertile or fertile women who are negative during pregnancy diagnostic tests (urine or seron- hCG). Fertile women who have "almost no chance of becoming pregnant" during the study period owing to the use of appropriate contraception (e.g., oral contraceptive pills, IUD, double-barrier method, or hormone implants) or men who have agreed to this
• People who have no problems in their nerves and mental systems and who can make their own doctors clear
• The person who agreed in writing to this test

You may not qualify if:

• Persons with hypersensitivity to probiotics
• Pregnant or lactating women
• People who have received other clinical trial drugs within the first 3 months of visit 1. (If the patient has received any other clinical trial drug within the past 3 months, contact the client's monitor to determine eligibility on a case-by-case basis.)
• A person who believes that the participant is in a condition or situation in which participation in the clinical trial may be hazardous to the participant
• Patients with severe congestive heart failure or severe angina
• If the patient is diagnosed as having lactose intolerance or immunosuppression
• Patients who are taking or taking medications (medicine for intestinal disorders, lactic acid bacteria) that may affect the test food, probiotics, or during the test period. However, if you are taking the drug, you can take the test after two weeks of abstinence.
• If the systolic blood pressure measured at Visit 1 is greater than 160 mmHg or diastolic blood pressure is greater than 100 mmHg and hypertension is not controlled regardless of whether the medication is administered or not.
• Patients with uncontrolled endocrine diseases (such as diabetes), metabolic diseases (e.g. secondary hyperlipidemia) or hypothyroidism (subjects with a history of hypothyroidism) should receive a stable thyroid hormone supplement for at least 4 weeks prior to visit 1 If you are on therapy, you can participate in this test only if the TSH level measured at Visit 2 is within the normal range.)
• If kidney function is impaired at visit 1 (creatinine\> 2.0 mg / dL) or nephrotic syndrome is observed
• If the cancer has developed within the past 5 years (unless it is determined to be cured)
• If there is a history of mental instability and drug / alcohol abuse within the past 5 years, or if major psychiatric illnesses are not adequately controlled and stabilized by medication
• Visits 1 If you have taken mental nerve agents within the previous 3 months
• If you take a systemic steroid preparation within 1 month before visit 1
• Patients who underwent abdominal surgery except for appendectomy, hernia surgery, and cesarean section

Sponsors & Collaborators

• IlDong Pharmaceutical Co Ltd: lead

MeSH Terms

Conditions

Irritable Bowel Syndrome

Condition Hierarchy (Ancestors)

Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: randomized, double-blind, placebo-controlled, parallel-group

Study Record Dates

• First Submitted: May 21, 2019
• First Posted: May 28, 2019
• Study Start: October 4, 2016
• Primary Completion: November 8, 2017
• Study Completion: January 22, 2018
• Last Updated: June 4, 2019

Record last verified: 2019-05

Data Sharing

• IPD Sharing: Will not share